Evidence map›Paper›PMID 37041587›Full record

ReviewStem cell research & therapy2023

Therapeutic potential of MSCs and MSC-derived extracellular vesicles in immune thrombocytopenia.

Feifeng Wu, Zhou She, Cuifang Li, Jueyi Mao, Senlin Luo, Xiaoyu Chen, Jidong Tian, Chuan Wen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Feifeng WuDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhou SheDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Cuifang LiDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jueyi MaoDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Senlin LuoDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Xiaoyu ChenDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jidong TianDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Chuan WenDepartment of Pediatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. chuanwen@csu.edu.cn.ORCID 0000-0001-6955-670X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune thrombocytopenia (ITP) is an acquired autoimmune disease involving a variety of immune cells and factors. Despite being a benign disease, it is still considered incurable due to its complex pathogenesis. Mesenchymal stem cells (MSCs), with low immunogenicity, pluripotent differentiation, and immunomodulatory ability, are widely used in a variety of autoimmune diseases. In recent years, impaired bone marrow mesenchymal stem cells (BMMSCs) were found to play an important role in the pathogenesis of ITP; and the therapeutic role of MSCs in ITP has also been supported by increasing evidence with encouraging efficacy. MSCs hold promise as a new approach to treat or even cure refractory ITP. Extracellular vesicles (EVs), as novel carriers in the "paracrine" mechanism of MSCs, are the focus of MSCs. Encouragingly, several studies suggested that EVs may perform similar functions as MSCs to treat ITP. This review summarized the role of MSCs in the pathophysiology and treatment of ITP.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsPurpura, Thrombocytopenic, IdiopathicCell DifferentiationHumansImmunomodulationCellular therapyExtracellular vesiclesImmune thrombocytopeniaMesenchymal stem cells

Identifiers

PMID37041587
PMCPMC10091587

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.